Compare OII & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | LQDA |
|---|---|---|
| Founded | 1964 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | OII | LQDA |
|---|---|---|
| Price | $23.30 | $33.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $25.00 | ★ $37.40 |
| AVG Volume (30 Days) | 742.2K | ★ 1.5M |
| Earning Date | 10-22-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | $69,216,000.00 |
| Revenue This Year | $5.93 | $904.79 |
| Revenue Next Year | $0.78 | $188.25 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | 8.71 | ★ 343.41 |
| 52 Week Low | $15.46 | $10.37 |
| 52 Week High | $28.31 | $35.54 |
| Indicator | OII | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 60.40 |
| Support Level | $26.76 | $32.11 |
| Resistance Level | $27.64 | $35.40 |
| Average True Range (ATR) | 0.91 | 1.54 |
| MACD | -0.37 | -0.16 |
| Stochastic Oscillator | 0.67 | 68.06 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.